Literature DB >> 19960200

Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation.

Michelangelo Mancuso1, Daniele Orsucci, Annalisa Logerfo, Anna Rocchi, Lucia Petrozzi, Claudia Nesti, Fabio Galetta, Gino Santoro, Luigi Murri, Gabriele Siciliano.   

Abstract

Mitochondrial diseases are due to impairment of the mitochondrial respiratory chain. A plausible pathogenic mechanism leading to cellular dysfunction and phenotypic expression is oxidative stress, but there are surprisingly few clinical studies on this subject. Glutathione (GSH) deficiency has been reported in mitochondrial diseases, and the biosynthesis of glutathione depends on cysteine availability. We have examined oxidative stress biomarkers [advanced oxidation protein products (AOPP) and ferric reducing antioxidant power (FRAP)] in blood samples from 27 patients and 42 controls. AOPP levels were greater in patients than in controls (P value <0.00001). Therefore, we performed a double-blind cross-over study to evaluate if 30-day supplementation with a whey-based cysteine donor could modify these markers, reduce lactate concentration during aerobic exercise, or enhance muscular strength and quality of life. Treatment did not modify lactate concentration, clinical scale (MRC) or quality of life (SF-36), but significantly reduced oxidative stress levels. Our findings reinforce the notions that in mitochondrial diseases oxidative stress is important and can be reduced by administration of a cysteine donor. Oxidative stress biomarkers may be useful to detect redox imbalance in mitochondrial diseases and to provide non-invasive tools to monitor disease status.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960200     DOI: 10.1007/s00415-009-5409-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

Review 1.  Mitochondrial respiratory-chain diseases.

Authors:  Salvatore DiMauro; Eric A Schon
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

2.  The definition and measurement of antioxidants in biological systems.

Authors:  B Halliwell; J M Gutteridge
Journal:  Free Radic Biol Med       Date:  1995-01       Impact factor: 7.376

3.  Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment.

Authors:  I P Hargreaves; Y Sheena; J M Land; S J R Heales
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency.

Authors:  Catarina M Quinzii; Luis C López; Jakob Von-Moltke; Ali Naini; Sindu Krishna; Markus Schuelke; Leonardo Salviati; Plácido Navas; Salvatore DiMauro; Michio Hirano
Journal:  FASEB J       Date:  2008-01-29       Impact factor: 5.191

5.  Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia.

Authors:  Kondala R Atkuri; Tina M Cowan; Tony Kwan; Angelina Ng; Leonard A Herzenberg; Leonore A Herzenberg; Gregory M Enns
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

6.  Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages.

Authors:  J W Heinecke; W Li; H L Daehnke; J A Goldstein
Journal:  J Biol Chem       Date:  1993-02-25       Impact factor: 5.157

7.  Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene.

Authors:  G Siciliano; A Tessa; S Petrini; M Mancuso; C Bruno; G S Grieco; A Malandrini; L DeFlorio; B Martini; A Federico; G Nappi; F M Santorelli; L Murri
Journal:  Neuromuscul Disord       Date:  2003-02       Impact factor: 4.296

8.  N-acetylcysteine inhibits muscle fatigue in humans.

Authors:  M B Reid; D S Stokić; S M Koch; F A Khawli; A A Leis
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

9.  Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis.

Authors:  G Siciliano; S Piazza; C Carlesi; A Del Corona; M Franzini; A Pompella; G Malvaldi; M Mancuso; A Paolicchi; L Murri
Journal:  J Neurol       Date:  2007-04-11       Impact factor: 4.849

10.  Advanced oxidation protein products as a novel marker of oxidative stress in uremia.

Authors:  V Witko-Sarsat; M Friedlander; C Capeillère-Blandin; T Nguyen-Khoa; A T Nguyen; J Zingraff; P Jungers; B Descamps-Latscha
Journal:  Kidney Int       Date:  1996-05       Impact factor: 10.612

View more
  21 in total

Review 1.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 2.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

Review 3.  Reversible infantile mitochondrial diseases.

Authors:  Veronika Boczonadi; Boglarka Bansagi; Rita Horvath
Journal:  J Inherit Metab Dis       Date:  2014-11-19       Impact factor: 4.982

Review 4.  Advances in drug therapy for mitochondrial diseases.

Authors:  Lufei Zhang; Zhaoyong Zhang; Aisha Khan; Hui Zheng; Chao Yuan; Haishan Jiang
Journal:  Ann Transl Med       Date:  2020-01

Review 5.  Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome.

Authors:  Shi-Bei Wu; Yi-Shing Ma; Yu-Ting Wu; Yin-Chiu Chen; Yau-Huei Wei
Journal:  Mol Neurobiol       Date:  2010-04-23       Impact factor: 5.590

6.  Acute liver failure after recommended doses of acetaminophen in patients with myopathies.

Authors:  Ilse Ceelie; Laura P James; Violette Gijsen; Ron A A Mathot; Shinya Ito; Coranne D Tesselaar; Dick Tibboel; Gideon Koren; Saskia N de Wildt
Journal:  Crit Care Med       Date:  2011-04       Impact factor: 7.598

7.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 8.  Treatment for mitochondrial disorders.

Authors:  Gerald Pfeffer; Kari Majamaa; Douglass M Turnbull; David Thorburn; Patrick F Chinnery
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 9.  New treatments for mitochondrial disease-no time to drop our standards.

Authors:  Gerald Pfeffer; Rita Horvath; Thomas Klopstock; Vamsi K Mootha; Anu Suomalainen; Saskia Koene; Michio Hirano; Massimo Zeviani; Laurence A Bindoff; Patrick Yu-Wai-Man; Michael Hanna; Valerio Carelli; Robert McFarland; Kari Majamaa; Douglas M Turnbull; Jan Smeitink; Patrick F Chinnery
Journal:  Nat Rev Neurol       Date:  2013-07-02       Impact factor: 42.937

Review 10.  Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases.

Authors:  M Mancuso; C Angelini; E Bertini; V Carelli; G P Comi; C Minetti; M Moggio; T Mongini; S Servidei; P Tonin; A Toscano; G Uziel; M Zeviani; G Siciliano
Journal:  Neuromuscul Disord       Date:  2012-12       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.